Vella Bioscience whose Women’s Pleasure Serum has been granted the brands first patent for the use of cannabinoids in treating Antidepressant-Induced Female Sexual Dysfunction by the Patent and Trademark Office (USPTO).
“Vella’s ability to do pharmaceutical-like research inside the sexual wellness consumer space is on full display with the grant of our first patent, and we expect several more to come,” said Vella Chief Executive Officer Nial DeMena. “Scientific innovation is Vella’s x-factor and the wellspring of our many disruptive products and technologies we have now and have ahead of us. As a company, we bring a certain ‘the future-is-now’ attitude to women’s sexual empowerment and pleasure that is wholly unique.”
The invention relates to compositions and methods containing hemp and/or cannabis-derived cannabidiol (CBD) as well as combinations with other active topical agents in treating female sexual dysfunction from the use of selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors (SNRIs), and other common antidepressants. Millions of women taking antidepressants discontinue treatment due to sexual side-effects, and that number continues to climb. Vella will form a wholly new pharmaceutical entity to now pursue an FDA-approved treatment.
“SSRI-induced sexual dysfunction is common in women and to date there is no effective treatment. Our newly issued patent covering our novel, topical approach to this disorder will be the impetus for the formation of a new company focused on this huge unmet need in women’s health. “Harin Padma-Nathan, MD, FRCS(C). Dr Harin Padma-Nathan has been the lead principal investigator (PI) for over 110 clinical trials, including Viagra.
Vella’s proprietary encapsulated liposomal on-demand CBD technology serves to advance a product portfolio of radical innovations for enhancing function in women and strengthening the promise of sexual empowerment for all. The patent grant, however, will lay the foundation for the upcoming spin-out pharmaceutical company that will use novel active topical agents to create an on-demand treatment for antidepressant-induced sexual dysfunction through a traditional FDA pathway.